Targeting Prostate Cancer with a Combination of WNT Inhibitors and a Bi-functional Peptide

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Prostate cancer is a prevalent malignancy in Western countries.
• Wingless-related integration site (WNT) inhibitors have demonstrated individual efficacy in cancer treatment.
• Investigating combination therapies is crucial for enhancing treatment outcomes.

Purpose of the Study:

• To evaluate the additive therapeutic effect of a bi-functional peptide combined with WNT inhibitors against prostate cancer.
• To determine if this combination therapy can enhance the efficacy of WNT inhibitors.

Main Methods:

• A bi-functional peptide (TP-LYT) with target and lytic domains was synthesized.
• Two WNT inhibitors, ethacrynic acid and ciclopiroxolamine, were used.
• Prostate cancer cells were treated with the peptide-inhibitor combinations and assessed using the WST-8 assay.

Main Results:

• A synergistic effect was observed between the bi-functional peptide and WNT inhibitors.
• The combination significantly increased the toxicity against prostate cancer cells.
• This suggests an enhanced anti-cancer activity when peptides and inhibitors are combined.

Conclusions:

• The combination therapy demonstrates a promising synergistic effect, enhancing prostate cancer cell death.
• This approach may enable the use of lower concentrations of WNT inhibitors, potentially leading to safer treatments.
• Further research into this combination therapy could offer new avenues for prostate cancer management.